Table V.
Multivariable analysis of progression-free survival with respect to treatment adjusted for UICC stage, age, Vimentin immunoreactivity, and interactions between treatment and Vimentin immunoreactivity.
| A, PFS of treatment adjusted for UICC stage and age (AIC=592.325) | ||
|---|---|---|
| Variable | HR (95% CI) | Wald chi-square P-value |
| PGB vs. EB | 0.458 (0.289–0.725) | 0.0009 |
| UICC stage IV vs. IIIB | 0.532 (0.274–1.034) | 0.0626 |
| Age (per year) | 0.979 (0.954–1.004) | 0.0951 |
| B, PFS of treatment adjusted for Vimentin immunoreactivity, and interactions between treatment and Vimentin immunoreactivity (AIC=594.103) | ||
| Variable | HR (95% CI) | Wald chi-square P-value |
| PGB vs. EB | Vimentin immunoreactivity=0: PGB vs. EB: 0.649 (0.382–1.105) | 0.1115 |
| Vimentin immunoreactivity >0: PGB vs. EB: 0.287 (0.123–0.668) | ||
| Vimentin immunoreactivity ≥8 vs. <8 | EB arm: Vimentin immunoreactivity >0 vs. 0: 1.337 (0.618–2.895) | 0.4610 |
| PGB arm: Vimentin immunoreactivity >0 vs. 0: 0.591 (0.321–1.087) | ||
| Vimentin immunoreactivity × treatment | – | 0.1072 |
PFS, progression-free survival; HR, hazard ratio; EB, erlotinib/bevacizumab; PGB, cisplatin/gemcitabine/bevacizumab; AIC, Akaike Information Criterion; UICC, Union for International Cancer Control.